GE Healthcare seeks permission for self manufacturing of Optison
If approved, GE will manufacture Optison at its Oslo facility thereby becoming the only contrast media manufacturer to supply its own stock to the US market. GE Healthcare
Ultragenyx Pharmaceutical has received accelerated approval from the US Food and Drug Administration (FDA) for its gene therapy, Genglycos (pariglasgene brecaparvovec-opnr), to treat glycogen storage disease type Ia (GSDIa).